5,6-dimethyl-1,10-phenanthroline - patents, research & applications

743Patents

32Research papers

93Patents - last 3 years

1Papers - last 3 years

Who owns the IP

The organizations most actively patenting around this compound, ranked by referenced patent volume.

#	Assignee	Patents
1	Lanxess AG	36
2	Shell PLC	30
3	Central Glass Co Ltd	27
4	Tokyo Ohka Kogyo Co Ltd	27
5	Toyobo Co Ltd	22

6	University of North Carolina System	20
7	Daikin Industries Ltd	18
8	3M Co	17
9	Danaher Corp	15
10	Eastman Kodak Co	14

Explore the full landscape

This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.

Visit Cypris

Where innovation is concentrated

Patent classifications ranked by volume reveal the technical domains with the most active filing.

#	Code	Area	Patents
1	`C07C`	Acyclic and carbocyclic compounds	154
2	`C07F`	Organometallic compounds	127
3	`B01J`	Chemical/physical processes (e.g. catalysts)	112
4	`C07D`	Heterocyclic compounds	102
5	`G01N`	Investigating / analysing materials	95

6	`C08L`	Polymer compositions (blends)	87
7	`C12Q`	Measuring/testing involving enzymes	81
8	`C09D`	Coatings, paints, varnishes	71
9	`H10K`	Organic semiconductors / OLEDs	64
10	`C08G`	Polymers from non-vinyl bonds (e.g. polyamides, polyesters)	57

AI mapped opportunity space

This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.

See Cypris in action

Representative patents

The filings that best characterise the patent activity around this compound, most-referenced first.

Title	Year	Assignee	Cited by
Osmium-containing redox mediator	1996	Roche Holding AG	452
Reagent including an osmium-containing redox mediator	1998	Roche Holding AG	280
Substituted benzo[4,5]imidazo[1,2-a]phenanthro[9,10-c][1,8]naphthyridines, benzo[4,5]imidazo[1,2-a]phenanthro[9,10-c][1,5]naphthyridines and dibenzo[f,h]benzo[4,5]imidazo[2,1-a]pyrazino[2,3-c]isoquinolines as thermally assisted delayed fluorescent materials	2019		48
NOVEL INTERMEDIATE FOR HALICHONDRIN B ANALOG SYNTHESIS AND NOVEL DESULFONYLATION REACTION USED FOR THE INTERMEDIATE	2009	Eisai Co Ltd	64
Redox reversible imidazole osmium complex conjugates	2001	Roche Holding AG	93

How research activity has moved

Papers published per year for this compound, over the last decade of indexed records.

Year	Papers
2022	1
2023	1

Who's driving the science

The most-published authors working with this compound, alongside their primary affiliations.

#	Author	Affiliation	Papers
1	Mallayan Palaniandavar	Bharathidasan University	8
2	Venugopal Rajendiran	Bharathidasan University	5
3	Hamed Alborzinia	Heidelberg University	3
4	Palanisamy Uma Maheswari	Bharathidasan University	3
5	Mohammad Abdulkader Akbarsha	Bharathidasan University	3

6	Larry A. Sklar	University of New Mexico	3
7	Igor Kitanović	Heidelberg University	3
8	Vaiyapuri Subbarayan Periasamy	Bharathidasan University	3
9	Eringathodi Suresh	Central Salt and Marine Chemicals Research Institute	3
10	Ingo Ott	Technische Universität Braunschweig	3

Research leaders

This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.

See Cypris in action

The literature that defines it

The most-cited papers anchoring the scientific record for this compound.

Title	Year	Cited by	Topic
Non-covalent DNA binding and cytotoxicity of certain mixed-ligand ruthenium(ii) complexes of 2,2′-dipyridylamine and diimines	2008	153	Metal complexes synthesis and properties
DNA binding and biological activity of some platinum(ii) intercalating compounds containing methyl-substituted 1,10-phenanthrolinesElectronic supplementary information (ESI) available: Binding data determined for platinum complexes bound to calf thymus DNA, linear dicroism spectra, Absorption spectra of the DNA alone and of the platinum complexes with DNA and solubilities of complexes in water. See http://www.rsc.org/suppdata/dt/b3/b316511f/	2004	134	Metal complexes synthesis and properties
Interaction of rac-[Cu(diimine)3]2+ and rac-[Zn(diimine)3]2+ complexes with CT DNA: effect of fluxional Cu(ii) geometry on DNA binding, ligand–promoted exciton coupling and prominent DNA cleavage	2008	93	Metal complexes synthesis and properties
Synthesis, characterization and DNA-binding properties of rac-[Ru(5,6-dmp)2(dppz)]2+ – Enantiopreferential DNA binding and co-ligand promoted exciton coupling	2005	87	Metal complexes synthesis and properties
Photophysical, Spectroscopic, and Computational Studies of a Series of Re(I) Tricarbonyl Complexes Containing 2,6-Dimethylphenylisocyanide and 5- and 6-Derivatized Phenanthroline Ligands	2005	82	Magnetism in coordination complexes

Frequently asked questions

Common questions about this compound's patent and research landscape, answered from the underlying data.

What is the molecular formula and weight of 5,6-dimethyl-1,10-phenanthroline?

5,6-dimethyl-1,10-phenanthroline has the molecular formula C14H12N2 and a molecular weight of 208.264.

Which companies hold the most patents involving this compound?

Lanxess AG leads with 36 patents, followed by Shell PLC with 30 patents, Central Glass Co Ltd and Tokyo Ohka Kogyo Co Ltd each with 27 patents, and Toyobo Co Ltd with 22 patents.

What are the primary research topics associated with this compound in published papers?

Published papers focus on metal complexes synthesis and properties, as well as magnetism in coordination complexes. Notable work includes studies on ruthenium, platinum, copper, and zinc complexes containing this ligand, with applications in DNA binding and biological activity.

What patent technology areas most frequently involve this compound?

The most common CPC subclasses are C07C (154 patents), C07F (127 patents), B01J (112 patents), C07D (102 patents), and G01N (95 patents), indicating applications in organic chemistry synthesis, organometallic compounds, chemical engineering, diagnostic analysis, and related fields.

How has patent activity involving this compound trended in recent years?

Patent filings have shown general growth, with 93 patents filed in the last 3 years. Annual filings reached a recent peak of 57 patents in 2024, compared to 24 patents in 2016, though 2025 and 2026 show lower counts likely due to incomplete data.